title: [Sjögren's syndrome: a new approach to treatment].
abstract: Södgren's syndrome treatment has essentially been based on symptomatic approach and has been of limited efficacy. Novel biological therapies targeting B cells, a key player in the pathophysiology of the syndrome, have recently been tested in controlled clinical trials and raise the hope of improving glandular and extraglandular manifestations of Söigren's syndrome.
authors.affiliation: Service d'immunologie et allergie CHUV, 1011 Lausanne. valeriane.rossier@unil.ch
authors.forename: V
authors.initials: V
authors.lastname: Rossier
authors.forename: P-A
authors.initials: PA
authors.lastname: Bart
authors.forename: F
authors.initials: F
authors.lastname: Spertini
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D018721:Muscarinic Agonists / Q000627:therapeutic use; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000150:complications / Q000188:drug therapy*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D018721:Muscarinic Agonists; D000069283:Rituximab